- Home
- DALN vs STRO Comparison
DALN vs STRO Comparison
Compare DALN & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- STRO
- Stock Information
- Founded
- DALN 1954
- STRO 2003
- Country
- DALN United States
- STRO United States
- Employees
- DALN N/A
- STRO N/A
- Industry
- DALN Newspapers/Magazines
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DALN Consumer Discretionary
- STRO Health Care
- Exchange
- DALN Nasdaq
- STRO Nasdaq
- Market Cap
- DALN 79.8M
- STRO 74.3M
- IPO Year
- DALN 2008
- STRO 2018
- Fundamental
- Price
- DALN $15.84
- STRO $0.89
- Analyst Decision
- DALN
- STRO Hold
- Analyst Count
- DALN 0
- STRO 7
- Target Price
- DALN N/A
- STRO $1.97
- AVG Volume (30 Days)
- DALN 65.6K
- STRO 598.8K
- Earning Date
- DALN 11-11-2025
- STRO 11-12-2025
- Dividend Yield
- DALN N/A
- STRO N/A
- EPS Growth
- DALN N/A
- STRO N/A
- EPS
- DALN N/A
- STRO N/A
- Revenue
- DALN $121,119,000.00
- STRO $104,473,000.00
- Revenue This Year
- DALN N/A
- STRO $65.42
- Revenue Next Year
- DALN N/A
- STRO N/A
- P/E Ratio
- DALN N/A
- STRO N/A
- Revenue Growth
- DALN N/A
- STRO N/A
- 52 Week Low
- DALN $3.66
- STRO $0.52
- 52 Week High
- DALN $16.10
- STRO $4.80
- Technical
- Relative Strength Index (RSI)
- DALN 73.38
- STRO 48.54
- Support Level
- DALN $14.22
- STRO $0.85
- Resistance Level
- DALN $14.87
- STRO $1.01
- Average True Range (ATR)
- DALN 0.17
- STRO 0.09
- MACD
- DALN -0.11
- STRO -0.01
- Stochastic Oscillator
- DALN 91.53
- STRO 16.63
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company. It operates The Dallas Morning News (dallasnews.com), Texas' newspaper. These operations generate revenue from advertising sales within the company's newspaper and digital platforms, subscriptions and retail sales of its newspaper, and commercial printing and distribution services predominantly related to national newspapers. In addition to traditional print and digital advertising, the company has a full-service agency, Medium Giant, offering businesses comprehensive, strategic, and creative marketing solutions. The company's two reportable segments are TDMN and Agency. Maximum revenue is derived from the TDMN segment, which comprises its traditional print business. The firm's customer base is concentrated in North Texas.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.